NCT04602975 - A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a | Biotech Hunter

Enrollment

248

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

April 12, 2023

Study Completion Date

November 15, 2023

Conditions

Healthy

Interventions

BIOLOGICAL

Injection SF2A-TT15 10 µg Adjuvanted

Intramuscular injection of experimental vaccine (adjuvanted 10 µg)

BIOLOGICAL

Injection SF2A-TT15 10 µg

Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)

BIOLOGICAL

Injection Adjuvanted Placebo

Intramuscular injection of Placebo with alhydrogel

BIOLOGICAL

Injection Placebo

Intramuscular injection of the not adjuvanted Placebo

BIOLOGICAL

Injection SF2A-TT15 2 µg Adjuvanted

Intramuscular injection of experimental vaccine (adjuvanted 2 µg)

BIOLOGICAL

Injection SF2A-TT15 2 µg

Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)

Trial Locations (1)

KEMRI / Henry M. Jackson Foundation Medical Research International, Kericho